CL2020002165A1 - Uso de tradipitant para tratar la cinetosis. - Google Patents
Uso de tradipitant para tratar la cinetosis.Info
- Publication number
- CL2020002165A1 CL2020002165A1 CL2020002165A CL2020002165A CL2020002165A1 CL 2020002165 A1 CL2020002165 A1 CL 2020002165A1 CL 2020002165 A CL2020002165 A CL 2020002165A CL 2020002165 A CL2020002165 A CL 2020002165A CL 2020002165 A1 CL2020002165 A1 CL 2020002165A1
- Authority
- CL
- Chile
- Prior art keywords
- tradipitant
- motion sickness
- treat motion
- treat
- sickness
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4192—1,2,3-Triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Hospice & Palliative Care (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Otolaryngology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Peptides Or Proteins (AREA)
- Steroid Compounds (AREA)
- Medicinal Preparation (AREA)
- Oscillators With Electromechanical Resonators (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862737992P | 2018-09-28 | 2018-09-28 | |
| US201962874927P | 2019-07-16 | 2019-07-16 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2020002165A1 true CL2020002165A1 (es) | 2021-01-04 |
Family
ID=68165866
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2020002165A CL2020002165A1 (es) | 2018-09-28 | 2020-08-21 | Uso de tradipitant para tratar la cinetosis. |
Country Status (20)
| Country | Link |
|---|---|
| US (2) | US20220249444A1 (https=) |
| EP (2) | EP3856338B1 (https=) |
| JP (1) | JP7468964B2 (https=) |
| KR (2) | KR102863233B1 (https=) |
| CN (1) | CN111918701B (https=) |
| AU (1) | AU2019348001B2 (https=) |
| BR (1) | BR112020015484A2 (https=) |
| CA (1) | CA3089238A1 (https=) |
| CL (1) | CL2020002165A1 (https=) |
| DK (1) | DK3856338T3 (https=) |
| ES (1) | ES3010832T3 (https=) |
| FI (1) | FI3856338T3 (https=) |
| HR (1) | HRP20250097T1 (https=) |
| HU (1) | HUE070000T2 (https=) |
| IL (1) | IL281569B2 (https=) |
| MX (1) | MX2020008456A (https=) |
| PT (1) | PT3856338T (https=) |
| SI (1) | SI3856338T1 (https=) |
| WO (1) | WO2020069092A1 (https=) |
| ZA (1) | ZA202004594B (https=) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2824552T3 (es) * | 2015-03-04 | 2021-05-12 | Vanda Pharmaceuticals Inc | Método de tratamiento con tradipitant |
| JP7791832B2 (ja) | 2020-03-26 | 2025-12-24 | バンダ・ファーマシューティカルズ・インコーポレイテッド | トラジピタントによる下気道感染症の治療 |
| WO2023019084A1 (en) * | 2021-08-12 | 2023-02-16 | Vanda Pharmaceuticals Inc. | Treatment of gastric accommodation with tradipitant |
| US20240350469A1 (en) | 2021-08-31 | 2024-10-24 | Vanda Pharmaceuticals Inc. | Treatment of lower respiratory tract infection with tradipitant |
| AU2023413130A1 (en) | 2022-12-21 | 2025-06-05 | Vanda Pharmaceuticals Inc. | Methods of treatment with tradipitant |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT1035115E (pt) * | 1999-02-24 | 2005-01-31 | Hoffmann La Roche | Derivados de 4-fenilpiridina e a sua utilizacao como antagonistas do receptor nk-1 |
| AU2003230829B8 (en) * | 2002-04-26 | 2008-12-11 | Eli Lilly And Company | Triazole derivatives as tachykinin receptor antagonists |
| BRPI0415010B8 (pt) * | 2003-10-24 | 2021-05-25 | Lilly Co Eli | formas cristalinas iv e v de {2-[1-(3,5-bis-trifluorometilbenzil)-5-piridin-4-il-1h-[1,2,3]triazol-4-il]-piridin-3-il)-(2-clorofenil)-metanona, (2-clorofenil)-[2-(2-hidróxi-2-piridin-4-il-vinil)piridin-3-il]metanona, seus processos de preparação, e composição farmacêutica sólida |
| EP2722045B1 (en) * | 2009-11-18 | 2016-07-06 | Helsinn Healthcare SA | Compositions for treating centrally mediated nausea and vomiting |
| ES2824552T3 (es) * | 2015-03-04 | 2021-05-12 | Vanda Pharmaceuticals Inc | Método de tratamiento con tradipitant |
| CN119074729A (zh) * | 2017-11-17 | 2024-12-06 | 万达制药公司 | 使用川地匹坦治疗胃肠疾病的方法 |
-
2019
- 2019-09-26 HU HUE19783926A patent/HUE070000T2/hu unknown
- 2019-09-26 FI FIEP19783926.9T patent/FI3856338T3/fi active
- 2019-09-26 BR BR112020015484-9A patent/BR112020015484A2/pt unknown
- 2019-09-26 WO PCT/US2019/053107 patent/WO2020069092A1/en not_active Ceased
- 2019-09-26 JP JP2020568453A patent/JP7468964B2/ja active Active
- 2019-09-26 EP EP19783926.9A patent/EP3856338B1/en active Active
- 2019-09-26 KR KR1020207022180A patent/KR102863233B1/ko active Active
- 2019-09-26 SI SI201930892T patent/SI3856338T1/sl unknown
- 2019-09-26 IL IL281569A patent/IL281569B2/en unknown
- 2019-09-26 MX MX2020008456A patent/MX2020008456A/es unknown
- 2019-09-26 AU AU2019348001A patent/AU2019348001B2/en active Active
- 2019-09-26 DK DK19783926.9T patent/DK3856338T3/da active
- 2019-09-26 EP EP24197970.7A patent/EP4450126A3/en not_active Withdrawn
- 2019-09-26 CA CA3089238A patent/CA3089238A1/en active Pending
- 2019-09-26 KR KR1020257030873A patent/KR20250140634A/ko active Pending
- 2019-09-26 CN CN201980018140.2A patent/CN111918701B/zh active Active
- 2019-09-26 ES ES19783926T patent/ES3010832T3/es active Active
- 2019-09-26 PT PT197839269T patent/PT3856338T/pt unknown
- 2019-09-26 HR HRP20250097TT patent/HRP20250097T1/hr unknown
-
2020
- 2020-07-24 ZA ZA2020/04594A patent/ZA202004594B/en unknown
- 2020-08-21 CL CL2020002165A patent/CL2020002165A1/es unknown
-
2022
- 2022-04-28 US US17/731,831 patent/US20220249444A1/en not_active Abandoned
-
2024
- 2024-05-01 US US18/652,776 patent/US20240285588A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP2022511194A (ja) | 2022-01-31 |
| JP7468964B2 (ja) | 2024-04-16 |
| EP3856338B1 (en) | 2024-11-06 |
| HRP20250097T1 (hr) | 2025-03-28 |
| CN111918701B (zh) | 2024-08-02 |
| BR112020015484A2 (pt) | 2021-04-27 |
| EP3856338A1 (en) | 2021-08-04 |
| NZ766397A (en) | 2023-09-29 |
| KR20250140634A (ko) | 2025-09-25 |
| ES3010832T3 (en) | 2025-04-04 |
| CA3089238A1 (en) | 2020-04-02 |
| EP4450126A3 (en) | 2025-02-19 |
| SI3856338T1 (sl) | 2025-04-30 |
| US20240285588A1 (en) | 2024-08-29 |
| US20220249444A1 (en) | 2022-08-11 |
| IL281569A (en) | 2021-05-31 |
| HUE070000T2 (hu) | 2025-04-28 |
| AU2019348001A1 (en) | 2020-08-06 |
| AU2019348001B2 (en) | 2023-09-21 |
| EP4450126A2 (en) | 2024-10-23 |
| PT3856338T (pt) | 2025-01-31 |
| FI3856338T3 (fi) | 2025-02-03 |
| IL281569B2 (en) | 2025-04-01 |
| IL281569B1 (en) | 2024-12-01 |
| ZA202004594B (en) | 2024-12-18 |
| WO2020069092A1 (en) | 2020-04-02 |
| DK3856338T3 (da) | 2025-02-10 |
| CN111918701A (zh) | 2020-11-10 |
| MX2020008456A (es) | 2020-09-25 |
| KR20210067980A (ko) | 2021-06-08 |
| KR102863233B1 (ko) | 2025-09-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2020002165A1 (es) | Uso de tradipitant para tratar la cinetosis. | |
| CL2019003126A1 (es) | Métodos de tratamiento mediante el uso de un compuesto inhibidor de jak. | |
| MX389468B (es) | Gliceril 3-hidroxibutiratos para el control de los síntomas de la migraña | |
| CL2018002099A1 (es) | Compuestos de piperidina sustituido y su uso | |
| CL2020001290A1 (es) | Método para el tratamiento de enfermedades gastrointestinales con tradipitant. | |
| CO2020015923A2 (es) | Antagonista de gremlin-1 para la prevención y tratamiento del cáncer | |
| CL2017002223A1 (es) | Métodos para el tratamiento de trastornos del movimiento involuntario anormal | |
| CL2017000285A1 (es) | Terapia combinada para el tratamiento de un paramixovirus | |
| CR20190071A (es) | Compuestos, composiciones y métodos para el tratamiento de enfermedades | |
| CL2018003451A1 (es) | Moduladores del receptor adrenergico beta-3 que sirve para el tratamiento o la prevensión de desordenes relacionados. | |
| UY37589A (es) | COMPUESTOS MODULADORES DEL RECEPTOR DE HIDROCARBUROS ARÍLICOS (AhR) | |
| ECSP21053104A (es) | Moduladores de la expresión de hsd17b13 | |
| AR113440A1 (es) | Tratamiento de glomeruloesclerosis focal y segmentaria con antagonistas de ccr2 | |
| UY37590A (es) | COMPUESTOS MODULADORES DEL RECEPTOR DE HIDROCARBUROS ARÍLICOS (AhR) | |
| MX2022004834A (es) | Anticuerpos inhibidores de via del factor tisular y usos de los mismos. | |
| MX385283B (es) | Tratamiento de cáncer usando 2-desoxi-2-fluoro-l-fucosa en combinación con un inhibidor del punto de control. | |
| AR112102A1 (es) | Tinostamustina para utilizar en el tratamiento de cáncer de ovario | |
| AR112144A1 (es) | Compuestos para el tratamiento del sarcoma | |
| MX2017000222A (es) | Metodos y composiciones para tratar la obesidad, prevenir el aumento de peso, promover la perdida de peso, promover el adelgazamiento o tratar o prevenir el desarrollo de la diabetes. | |
| AR110404A1 (es) | MÉTODOS PARA EL TRATAMIENTO DE ENFERMEDADES FIBRÓTICAS UTILIZANDO EL INTERFERÓN-l | |
| MX2021011507A (es) | Compuestos farmaceuticos para el tratamiento de trastornos mediados por complemento. | |
| CL2019003325A1 (es) | Uso novedoso de un agonista del receptor 2 de formil péptido / receptor a4de lipoxina (fpr2 / alx) para el tratamiento de la insuficiencia cardíaca. | |
| MX375277B (es) | Métodos para tratar el síndrome de prader-willi | |
| CO2022001354A2 (es) | Métodos para tratar o prevenir la atrofia muscular espinal | |
| MX379289B (es) | Uso de agonistas del receptor nicotinico de acetilcolina alfa 7. |